Evidence map›Paper›PMID 42342967›Full record

ArticleBone marrow transplantation2026

Safety, efficacy and feasibility of GCSF and plerixafor based CD34 mobilization for backup autologous stem cell collection in patients undergoing alternate donor hematopoietic stem cell transplant for sickle cell disease: Take away lessons for gene therapy.

Garima Nirmal, Vaibhav Chadha, Shruti Verma, Eby P Baby, Nikhil Gupta, Mohit Chaudhary, Uday Thakur, Gaurav Kharya

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Garima NirmalCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.ORCID http://orcid.org/0000-0002-7258-6659
Vaibhav ChadhaCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.
Shruti VermaCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.
Eby P BabyCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.
Nikhil GuptaCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.
Mohit ChaudharyDepartment of Transfusion Medicine & Immunology, Indraprastha Apollo Hospital, New Delhi, India.
Uday ThakurDepartment of Transfusion Medicine & Immunology, Indraprastha Apollo Hospital, New Delhi, India.
Gaurav KharyaCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India. gaurav.kharya@gmail.com.ORCID http://orcid.org/0000-0003-2181-1825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A retrospective analysis was performed on 70 patients with SCD aged <30 years, who underwent alternate donor HSCT, in whom autologous stem cell was collected as backup. Patients received 3-4 days of 10 mcg/kg GCSF with plerixafor 0.24 mg/kg 6-8 h prior to PBSC harvest and a desired target CD34 + count of > 3 million/ Kg recipient body weight was collected. Median age of cohort was 10 years (1-27 years). Median CD34 dose per collection was 7.7 × 10

Indexed as

Anemia, Sickle CellAntigens, CD34Genetic TherapyGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHeterocyclic CompoundsAdolescentAdultBenzylaminesChildChild, PreschoolCyclamsFeasibility StudiesFemaleHumansAntigens, CD34BenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHeterocyclic Compoundsplerixafor

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.